Paper published in a journal (Scientific congresses and symposiums)
#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
Banerjee, Susana N; Ring, Kari L; Niewenhuysen, Els Van et al.
2023In International Journal of Gynecological Cancer, 33, p. 20-A21
Peer reviewed
 

Files


Full Text
ESGO 2023 VERASTEM.pdf
Publisher postprint (525.6 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Disciplines :
Oncology
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Banerjee, Susana N
Ring, Kari L
Niewenhuysen, Els Van
Fabbro, Michel
Aghajanian, Carol
Oaknin, Ana
Colombo, Nicoletta
Santin, Alessandro D
Clamp, Andrew R
Moore, Kathleen N
Rose, Peter G
David M, O’Malley
Chon, Hye Sook
Salinas, Erin A
Prendergast, Emily N
Lustgarten, Stephanie
Rodrigues, Manuel
Gennigens, Christine  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Monk, Bradley J
Grisham, Rachel N
More authors (10 more) Less
Language :
English
Title :
#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
Publication date :
September 2023
Event name :
ESGO's 24th European Gynaecological Oncology Congress
Event date :
28/09/2023 au 1/10/2023
Audience :
International
Journal title :
International Journal of Gynecological Cancer
eISSN :
1525-1438
Volume :
33
Pages :
A20-A21
Peer reviewed :
Peer reviewed
Available on ORBi :
since 23 December 2023

Statistics


Number of views
78 (6 by ULiège)
Number of downloads
1 (1 by ULiège)

Bibliography


Similar publications



Contact ORBi